Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFT: Pyridostigmine and Low-Dose Naltrexone in ME/CFS and Long COVID
NCT06366724Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pyridostigmine, naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), post-COVID-19 condition (PCC), sponsored by Brigham and Women's Hospital. Started Sep 2024; status: recruiting.
02
Drugs
pyridostigminenaltrexone
03
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06366724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366724.